19th Ave New York, NY 95822, USA

Grup de Modelització de Teràpies Antitumorals

Models of Cancer Therapies Group VHIO

El nostre grup se centra en l’oncoproteïna pleotròpica i ubiqua Myc, la desregulació de la qual està implicada en gairebé tots els càncers humans. Les dificultats tècniques de dirigir-se a factors de transcripció nuclears com Myc —i la preocupació pels possibles efectes secundaris— havien impedit fins fa poc qualsevol validació preclínica de la inhibició de Myc com a possible estratègia terapèutica.

En els darrers anys, hem demostrat en diversos models murins que la inhibició de Myc té un impacte terapèutic espectacular en diversos tipus de tumor, amb efectes secundaris molt lleus i reversibles en el teixit normal.

Encoratjats pels nostres resultats en ratolins, ara estem desenvolupant opcions farmacològiques viables i no tòxiques per dirigir-nos a Myc a la clínica. Per això, vam crear una empresa derivada, Peptomyc SL, per al desenvolupament de pèptids inhibidors de Myc per a la teràpia del càncer. Actualment el nostre laboratori, en col·laboració amb Peptomyc, està validant el nostre nou enfocament contra càncers considerablement difícils de tractar que són resistents als tractaments estàndard i que necessiten urgentment noves vies terapèutiques (és a dir, el càncer de pulmó no microcític impulsat per KRAS, el càncer colorectal amb mutació RAS i el càncer de mama triple negatiu metastàtic).

El nostre grup ha continuat contribuint a la recerca del càncer en general i, més concretament, com a líder en el camp de Myc.

Laura Soucek
Cap de Grup
Jonathan_Richard
Jonathan R. Whitfield
Investigador sènior
  • Validar preclínicament noves estratègies terapèutiques contra Myc en els càncers de mama, cervell i pulmó, el neuroblastoma, el melanoma, el càncer colorectal i el mieloma múltiple.
  • Validar les miniproteïnes anti-Myc de penetració cel·lular basades en Omomyc per a la teràpia del càncer.
  • Definir la funció de Myc en la promoció de l’evasió immunològica del càncer i provar l’eficàcia dels inhibidors de Myc i els tractaments combinats d’IO en el tractament del càncer.
  • Investigar com funciona la xarxa Myc en els tumors de l’estroma gastrointestinal (TEGI) defectuosos i en el càncer de pulmó microcític (CPMC) per definir dianes d’actuació que abordin aquestes necessitats clíniques no cobertes.

Figura: Adaptat de Massó-Vallés i Soucek, 2020: Representació de l’estructura cristal·lina del dímer MYC/MAX (1NKP, esquerra) i del dímer Omomyc/Omomyc (5I50, dreta) bHLHZ unit a l’ADN.

Models of Cancer Therapies Group VHIO
Cap de grup
Laura Soucek
Investigador sènior
Jonathan R. Whitfield
Associat de recerca
Mariano F. Zacarías-Fluck
Becàries postdoctorals
Jastrinjan Kaur
Tècnics
Génesis Martín Fernandez
Erika Serrano del Pozo
Estudiants de doctorat
Fabio Giuntini
Íñigo González-Larreategui

Publicacions científiques més rellevants

  • Whitfield JR, Soucek L. The long journey to bring a Myc inhibitor to the clinic. J Cell Biol. 2021 Aug 2;220(8):e202103090.
  • Zacarías-Fluck MF, Jauset T, Martínez-Martín S, Kaur J, Casacuberta-Serra S, Massó-Vallés D, Serrano Del Pozo E, Martín-Fernández G, González-Larreategui Í, López-Estévez S, Brown-Swigart L, Beaulieu ME, Whitfield JR, Madan B, Virshup DM, Evan GI, Soucek L. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Life Sci Alliance. 2021 Mar 2;4(5):e201900490. Print 2021 May.
  • Martínez-Martín S, Soucek L. MYC inhibitors in multiple myeloma. Cancer Drug Resist 2021;4:842-65.10.20517/cdr.2021.55.
  • Whitfield J, Soucek L. An “-omycs” Toolbox to Work with MYC. Methods Mol Biol. 2021;2318:1-11
  • Beaulieu ME, Castillo F, Soucek L. Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells. 2020 Apr22;9(4):1038.
  • Massó-Vallés D, Soucek L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020 Apr 4;9(4):883. doi: 10.3390/ cells9040883.PMID: 32260326
  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano del Pozo E, Fiore C, Foradada L, Castillo Cano V, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MA, Whitfield JR, Lavigne P, Soucek L. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019 Mar 20;11(484).
  • Beaulieu ME, Soucek L. Finding MYCure. Mol Cell Oncol. 2019 Jun 20;6(5):e1618178.
  • Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix, Sandra Mancilla R, Fernández Y, Rinas U, Schwartz Jr S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies. Adv Sci. 2019 Jul 24.
  • Whitfield JR, Soucek L. Editorial Overview: Peptides in Cancer. Curr Opin Pharmacol. 2019 Jun 27. pii: S1471-4892(19)30045-1.
  • Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med. 2019 Mar 20;11(484). Link to Abstract
  • Jauset T, Massó-Vallés D, Martínez-Martín S, Beaulieu ME, Foradada L, Fiorentino FP, Yokota J, Haendler B, Siegel S, Whitfield JR, Soucek L. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget. 2018 Apr 10;9(27):18734-18746.
  • Dang C, Reddy EP, Shokat K, and Soucek L. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017 Aug;17(8):502-508.
  • Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivanco A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene. 2017 Oct 5;36(40):5639-5647.
  • Whitfield JR, Beaulieu ME, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol. 2017 Feb 23;5:10. eCollection 2017.
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models. Nat Rev Cancer. 2017 Apr;17(4):254-268.
  • Massó-Vallés D, Jauset T, Soucek L. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. 2016 Jun 10;3(5-6):147-8.
  • Fiorentino FP, Tokgün E, Solé-Sánchez S, Giampaolo S, Tokgün O, Jauset T, Kohno T, Perucho M, Soucek L, Yokota J. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation.  Oncotarget. 2016 May 24;7(21):31014-28.
  • Daniel Massó-Vallés, Toni Jauset and Laura Soucek. Ibrutinib repurposing: from B cell malignancies to solid tumors. Oncoscience. Onlibe Advanced Publication DOI: 10.18632/oncoscience.310. Editorial.
  • Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, Laura Soucek, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.
  • Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi,  Neetu Singh, Laura Soucek, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. Review.
  • Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and Laura Soucek. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.
  • Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, , Joan Seoane, Gerard I Evan, and Laura Soucek. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. Article.
  • Laura Soucek, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.
  • Whitfield J, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.
  • Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and Laura Soucek. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8. Article.
  • Andrew Finch*, Laura Soucek*, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. *Joint first authors
  • Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.
  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.
  • Maria A. Christophorou, Dionisio Martin-Zanca, Laura Soucek, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo.Nature Genetics. 2005 Jul;37(7):718-26. Article.
  • Laura Soucek, Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.
  • Laura Soucek and Gerard Evan. Myc – is this the oncogene from Hell?. Cancer Cell. 2002 June; 1(5): 406-408. Review.
  • Laura Soucek, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis. Cancer Res. 2002; 62: 3507-3510. Article.
  • Soucek L., Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.

Totes les publicacions

  • Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, Wang Q, López C, Bernhart SH, Grande BM, Poggio T, Langellotto F, Bonello L, Dall’Olio R, Martínez-Martín S, Molinaro L, Francia di Celle P, Whitfield JR, Soucek L, Voena C, Calogero RA, Morin RD, Staudt LM, Siebert R, Zamò A, Chiarle R. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Adv. 2021 Dec 14;5(23):5239-5257. doi: 10.1182/bloodadvances.2021005682.
  • Martínez-Martín S, Soucek L. MYC inhibitors in multiple myeloma. Cancer Drug Resist2021;4:842-65.20517/cdr.2021.55.  Review.
  • Whitfield JR, Soucek L. The long journey to bring a Myc inhibitor to the clinic. J Cell Biol. 2021 Aug 2;220(8):e202103090. doi: 10.1083/jcb.202103090. Epub 2021 Jun 23.
  • Whitfield J, Soucek L. An “-omycs” Toolbox to Work with MYC. Methods Mol Biol. 2021;2318:1-11. doi: 10.1007/978-1-0716-1476-1_1.
  • Mariano F. Zacarías-Fluck, Toni Jauset, Sandra Martínez-Martín, Jastrinjan Kaur, Sílvia Casacuberta-Serra, Daniel Massó-Vallés, Erika Serrano del Pozo, Génesis Martín-Fernández, Íñigo González-Larreategui, Sergio López-Estévez, Lamorna Brown-Swigart, Marie-Eve Beaulieu, Jonathan R. Whitfield, Babita Madan, David M. Virshu4, Gerard I. Evan and Laura Soucek. The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. Life Sci Alliance. 2021 Mar;4(5). DOI: 10.26508/lsa.2019004902021. Article.
  • Paola Pellanda, Mattia Dalsass, Marco Filipuzzi, Alessia Loffreda, Alessandro Verrecchia, Virginia Castillo Cano, Hugo Thabussot, Mirko Doni, Marco J. Morelli, Laura Soucek, Theresia Kress, Davide Mazza, Marina Mapelli, Marie-Eve Beaulieu, Bruno Amati and Arianna Sabò. Integrated requirement of non-specific and sequence-specific DNA binding in MYC-driven transcription. EMBO J. 2021. DOI: 10.15252/embj.2020105464.
  • Beaulieu ME, Castillo F, Soucek L. Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein. Cells. 2020 Apr 22;9(4). pii: E1038. doi: 10.3390/cells9041038. Review.
  • Massó-Vallés D. and Soucek L. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. Cells. 2020, 9, 883; doi:10.3390/cells9040883. Review.
  • Daniel Massó-Vallés, Marie-Eve Beaulieu and Laura Soucek. “MYC, MYCL and MYCN as therapeutic targets in lung cancer”. Expert Opin Ther Targets. 2020 Jan 31. doi: 10.1080/14728222.2020.1723548. Review.
  • Nicole Sodir, Roderik Kortlever, Valentin Barthet, Tania Campos, Luca Pellegrinet, Steven Kupczak, Panayiotis Anastasiou, Lamorna Brown-Swigart, Laura Soucek, Mark Arends, Trevor Littlewood, and Gerard Evan. “Myc instructs and maintains pancreatic adenocarcinoma phenotype”. Cancer Discov. 2020 Jan 15. pii: CD-19-0435. doi: 10.1158/2159-8290.CD-19-0435. Article.
  • Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso, Paloma Bragado, Marselina Arshakyan, Iuliana-Cristiana Luis, Albert Marín, Sebastian Morán, Manuel Castro, Gemma Fuster, Sabrina Gea-Sorli, Toni Jauset, Laura Soucek, Luis Montuenga, Manel Esteller, Eduard Monsó, Víctor Ivo Peinado, Pere Gascón, Cristina Fillat, Frank Hilberg, Noemí Reguart, Jordi Alcaraz. “Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma”. Cancer Res. 2020 Jan 15;80(2):276-290. doi: 10.1158/0008-5472.CAN-19-0637. Article.
  • Mireia Pesarrodona, Toni Jauset, Zamira V. Díaz-Riascos, Alejandro Sánchez-Chardi, Marie-Eve Beaulieu, Joaquin Seras-Franzoso, Laura Sánchez-García, Ricardo Baltà-Foix, Sandra Mancilla, Yolanda Fernández, Ursula Rinas, Simó Schwartz Jr, Laura Soucek, Antonio Villaverde, Ibane Abasolo, and Esther Vázquez. “Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies”. Advanced Sciences. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. A
  • Jonathan R. Whitfield and Laura Soucek. Editorial Overview: Peptides in Cancer. Current Opinion in Pharmacology. 2019 Jun 27. pii: S1471-4892(19)30045-1. Doi: 1016/j.coph.2019.06.001.  Editorial.
  • Marie-Eve Beaulieu and Laura Soucek. Finding MYCure. Mol Cell Oncology. 2019. Doi: 1080/23723556.2019.1618178. Author’s View.
  • Ramón Y Cajal S, Sancho P, Soucek L, Peinado H, Abad M, Valiente M, Efeyan A, Pardo J, Quesada V, Jimeno J, Duque PM, Antón A, Varela I, Schuhmacher AJ. A spotlight on cancer researchers in Spain: new paradigms and disruptive ideas. Clin Transl Oncol. 2019 Aug 9. doi: 10.1007/s12094-019-02199-4.
  • Marie-Eve Beaulieu, Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Peter Rahl, Loïka Maltais, Mariano F. Zacarias-Fluck, Sílvia Casacuberta-Serra, Erika Serrano del Pozo, Christopher Fiore, Laia Foradada, Virginia Castillo Cano, Matthew Guenther, Eduardo Romero Sanz, Marta Oteo, Cynthia Tremblay, Génesis Martín, Danny Letourneau, Martin Montagne, Miguel Ángel Morcillo Alonso, Jonathan R. Whitfield, Pierre Lavigne and Laura Soucek. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-Myc therapy. Sci Trans Med. 2019 Mar 20;11(484). Doi: 10.1126/scitranslmed.aar5012. Article.
  • Irina Alimova, Angela Pierce, Etienne Danis, Andrew Donson, Diane K Birks, Andrea Griesinger, Nicholas K Foreman, Mariarita Santi, Laura Soucek, Sujatha Venkataraman & Rajeev Vibhakar. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1 deficient Group 2 Atypical Teratoid Rhabdoid Tumors to suppress tumor growth in vivo. Int J Cancer. 2019 Apr 15;144(8):1983-1995. doi: 10.1002/ijc.31873. Article.
  • Sílvia Casacuberta-Serra and Laura Soucek. Myc and Ras, the Bonnie and Clyde of immune evasion. Translational Cancer Research. 2018 Feb ;7(Suppl 4):S457-S459. doi: 10.21037/tcr.2018.03.09.
  • Toni Jauset, Daniel Massó-Vallés, Sandra Martínez-Martín, Marie-Eve Beaulieu, Laia Foradada, Francesco Paolo Fiorentino, Jun Yokota, Bernard Haendler, Stephan Siegel, Jonathan R. Whitfield and Laura Soucek. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. 2018 Apr 10;9(27):18734-18746. doi: 10.18632/oncotarget.24648. Article.
  • Chi Dang, E Premkumar Reddy, Kevan Shokat, and Laura Soucek. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017 Jun 23. doi: 10.1038/nrc.2017.36. Review.
  • Kim Pedersen, Faiz Bilal, Cristina Bernadó Morales, Maria Teresa Salcedo, Teresa Macarulla, Daniel Massó-Vallés, Vishnu Mohan, Ana Vivanco, Maria-Josep Carreras, Xavier Serres, Monder Abu-Suboh, Joaquim Balsells, Elena Allende, Irit Sagi, Laura Soucek, Josep Tabernero and Joaquín Arribas. Pancreatic cancer heterogeneity and response to Mek inhibition. 2017 Jun 5. doi: 10.1038/onc.2017.174. [Epub ahead of print]. Article.
  • Loïka Maltais, Martin Montagne, Mikaël Bédard, Cynthia Tremblay, Laura Soucek and Pierre Lavigne. Biophysical Characterization of the b-HLH-LZ of ΔMax, an Alternatively Spliced Isoform of Max Found in Tumor Cells: Towards the Validation of a Tumor Suppressor Role for the Max Homodimer. PLoS One. 2017 Mar 28; 12(3): e0174413. https://doi.org/10.1371/journal.pone.0174413. Article.
  • Jonathan R Whitfield, Marie-Eve Beaulieu, Laura Soucek. Strategies to inhibit Myc and their clinical applicability. Cell Dev. Biol., 23 February 2017 | https://doi.org/10.3389/fcell.2017.00010. Review.
  • Annette T. Byrne, Denis G. Alférez, Frederic Amant, Daniela Annibali, Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna,  Eva Budinská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S. Gail Eckhard, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika Jarzabek, Steven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti and Livio Trusolino. Interrogating open issues in cancer precision medicine using Patient-Derived Xenograft Models.  Nat Rev Cancer. 2017 Jan 20. doi: 10.1038/nrc.2016.140. [Epub ahead of print]. Review.
  • E. Beaulieu, T. Jauset, D. Massó-Vallés, L. Soucek* and J.R. Whitfield. Mouse Models in Personalized Cancer Medicine. Chapter 6 of Cancer genetics and Genomics for Personalized Medicine. 2017. ISBN: 9789814669887. Book Chapter. *Corresponding author.
  • Soucek L, Torrens L, Pujades C and Claría J. Experimental Handbook of Translational Medicine. Medica UB. 2016. ISBN: 978-84-475-4030-3. Book chapter.
  • Daniel Massó-Vallés, Toni Jauset and Laura Soucek. Ibrutinib repurposing: from B cell malignancies to solid tumors. 2016 Jun 10;3(5-6):147-8.DOI: 10.18632/oncoscience.310. Review.
  • Francesco Paolo Fiorentino, Elvan Tokgün, Sònia Solé-Sánchez, Sabrina Giampaolo, Onur Tokgün, Toni Jauset, Takashi Kohno, Manuel Perucho, Laura Soucek, Jun Yokota. Growth Suppression by MYC Inhibition in Small Cell Lung Cancer Cells with TP53 and RB1 Inactivation. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print] Article.
  • Cecconi F, Soucek L, Taub DD, Ziparo E. Live or Die: Choice Mechanisms in Stressed Cells. Mediators Inflamm. 2015; 2015:454863. Epub 2015 Oct 8. Editorial.
  • William H. Goodson III, Leroy Lowe, David O. Carpenter, Michael Gilbertson, Abdul Manaf Ali, Adela Lopez de Cerain Salsamendi, […], Laura Soucek, […], Zhiwei Hu. Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review.
  • Stephanie C. Casey, Monica Vaccari, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Mary Helen Barcellos-Hoff, Dustin Brown, Marion Chapellier, […], Sandra Ryeom, Hosni K. Salem, Ivana Scovassi, Neetu Singh, Laura Soucek, Louis Vermeulen, Jonathan R. Whitfield, Jordan Woodrick, Annamaria Colacci, William H. Bisson, and Dean W. Felsher. Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.
  • Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Eve Beaulieu, Gerard I. Evan, Laurence Elias, Joaquín Arribas and Laura Soucek. Ibrutinib exerts potent anti-fibrotic and anti-tumor activity in mouse transgenic and patient derived xenograft models of pancreatic adenocarcinoma. Cancer Res. 2015 Apr 15; 75(8): 1675-1681. Article.
  • Whitfield J, Littlewood T, Evan GI, Soucek L. The estrogen receptor fusion system in mouse models: a reversible switch. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):pdb.top069815. doi: 10.1101/pdb.top069815. Book chapter.
  • Whitfield J, Littlewood T, Soucek L. Tamoxifen administration to mice. Cold Spring Harb Protoc. 2015 Mar 2;2015(3):pdb.prot077966. doi: 10.1101/pdb.prot077966. Book chapter.
  • Daniela Annibali, Jonathan R Whitfield, Emilia Favuzzi, Toni Jauset, Erika Serrano, Isabel Cuartas, Sara Redondo-Campos, Gerard Folch, Alba Gonzàlez-Juncà, Nicole M Sodir, Daniel Massó-Vallés, Marie-Eve Beaulieu, Lamorna B Swigart, Margaret M Mc Gee, Maria Patrizia Somma, Sergio Nasi, Joan Seoane, Gerard I Evan, and Laura Soucek. Myc Inhibition as a Therapeutic Strategy Against Glioma: a Role for Myc in Proficient Mitosis. Nat Communications. 2014 Aug 18;5:4632. doi: 10.1038/ncomms5632.
  • Book: “The Myc gene”, Methods and Protocols, Series: Methods in Molecular Biology, Vol. 1012. Soucek, Laura; Sodir, Nicole M. (Editors) 2013. A product of Humana Press.
  • Nicole M. Sodir and Laura Soucek. Chapter: The Myc world within reach. “Myc: Methods and Protocols” Book, Methods Mol Biol. 2013;1012:1-6. Book chapter.
  • Laura Soucek, Jonathan R. Whitfield, Nicole M. Sodir, Daniel Massó-Vallés, Erika Serrano, Anthony N. Karnezis, Lamorna Brown Swigart and Gerard I. Evan. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013 Mar 1;27(5):504-13. Article.
  • Whitfield J, Soucek L. Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci. 2012, 69(6), 931-934. Review.
  • Oscar M. Pello, Maria De Pizzol, Massimiliano Mirolo, Laura Soucek, Luca Zammataro, Angelo Amabile, Andrea Doni, Lamorna B. Swigart, Gerard I. Evan, Alberto Mantovani, Massimo Locati. c-Myc controls alternative activation of human macrophages and tumor-associated macrophage biology. 2012,  119(2), 411-421. Article.
  • Laura Soucek, Joseph J Buggy, Roderik Kortlever, Shanthi Adimoolam, Lamorna Brown Swigart and Gerard Evan. Modeling mast cell inhibition by PCI-32765 as potential therapy for insulinoma. 2011; 13(11):1093–100. Article.
  • Mauro Savino, Daniela Annibali, Nicoletta Carucci, Laura Soucek, Gerard Evan, Sergio Nasi. The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy. PLoS One. 2011;6(7):e22284. Epub 2011 Jul 21. Article.
  • Nicole M Sodir, Lamorna Brown Swigart, Anthony N Karnezis, Douglas Hanahan, Gerard Evan and Laura Soucek. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011 May 1;25(9):907-16. Epub 2011 Apr 8.
  • Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, Soucek L, Naomoto Y. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res. 2010 Oct;30(10):4193-200.
  • Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev. 2010 Feb;20(1):91-95. Epub 2009 Dec 3. Review.
  • Andrew Finch*, Laura Soucek*, Melissa Junttila, Lamorna Brown Swigart and Gerard I. Evan. Acute over-expression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/β-catenin pathway activation. Mol Cell Biol. 2009 Oct;29(19):5306-15. Epub 2009 Jul 27. Article. *Joint first authors
  • Laura Soucek, Jonathan Whitfield, Carla P. Martins, Andrew J. Finch, Nicole M. Sodir, Lamorna Brown Swigart, Sergio Nasi and Gerard I. Evan. Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83. Epub 2008 Aug 17. Article.
  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors.
    Nat Med. 2007 Oct;13(10):1211-8. Epub 2007 Sep 30. Article.
  • Finch A, Prescott J, Shchors K, Hunt A, Soucek L, Dansen TB, Swigart LB, Evan GI. Bcl-x(L) gain of function and p19(ARF) loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell. 2006 Aug;10(2):113-120. Article.
  • Elizabeth R. Lawlor, Laura Soucek, Lamorna Brown-Swigart, Ksenya Shchors, Uli Bialucha, Gerard I. Evan. Reversible Kinetic Analysis of Myc Targets In vivo Provides Novel Insights into Myc-Mediated Tumorigenesis. Cancer Res. 2006 May 1;66(9):4591-601. Article.
  • Maria A. Christophorou, Dionisio Martin-Zanca, Laura Soucek, Elizabeth Lawlor, Emmy Verschuren, Lamorna Brown-Swigart and Gerard I. Evan. Temporal dissection of p53 function in vitro and in vivo. Nature Genetics. 2005 Jul;37(7):718-26. Article.
  • Laura Soucek, Sergio Nasi, and Gerard Evan. Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ. 2004 Sep;11(9):1038-45. Article.
  • Satoshi Kanasawa, Laura Soucek, Gerard Evan, Takashi Okamoto, and B. Matija Peterlin. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene. 2003 Aug 28;22(36):5707-11. Article.
  • Laura Soucek and Gerard Evan. Myc – is this the oncogene from Hell?. Cancer Cell. 2002 June; 1(5): 406-408. Review.
  • Laura Soucek, Richard Jucker, Laura Panacchia, Ruggero Ricordy, Franco Tatò, and Sergio Nasi. Omomyc, a Potential Myc Dominant Negative, Enhances Myc-induced Apoptosis . Cancer Res. 2002; 62: 3507-3510. Article.
  • Mandolesi G, Gargano S, Pennuto M, Illi B, Molfetta R, Soucek L, Mosca L, Levi A, Jucker R, Nasi S. NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction. FEBS Lett. 2002. ¡ 510(1-2):50-6. Article.
  • Sergio Nasi, Roberta Ciarapica, Richard Jucker, Jessica Rosati and Laura Soucek. Making decisions through Myc. FEBS. 2001. 490(3): 153-162. Review.
  • Sergio Nasi and Laura Soucek. p53 Gene e Proteina, Enciclopedia Medica Italiana, Tomo III, 2000, 4313-4323. Book chapter.
  • Soucek L., Citterich M.H., Sacco A., Jucker R., Cesareni G. and Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998, 17(19): 2463-2472. Article.

Project Title: Identification of clinical biormakers of response to MYC inhibition in cancer treatment.
Principal Investigators: Laura Soucek
Funding Agency: Spanish Ministry of Economy, Industry and Competitiveness “Retos de Colaboración” Grant.
Duration: 2020-2023

Instituto de Salud Carlos III: Proyectos FIS de Investigación en Salud.
Title: Validation of new anti-Myc therapy in Melanoma. 2020-2023.
PI: Laura Soucek
Awarded in 2019.

Fundació La Marató de TV3
Title: Overcoming immunotherapeutic resistance through Myc inhibition in KRas-driven NSCLC with diverse mutational landscape.
2020-2022.
Project Director: Laura Soucek. Co-participant: Silvestre Vicent Cambra.

Canadian Institutes of Health Research Grant
Title: Development of cancer therapies targeting Myc with cell penetrating b-HLH-LZ domains.
2018-2023.
Role: Co-applicant.

H2020 INFRAIA 2017
Title: EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts.
2017-2021.
Role: Co-applicant5. I+D+I en Líneas Estratégicas en colaboración público-privada, Spanish Ministry of Economy, Industry and Competitiveness. Title: Using MYC inhibition to overcome immunotherapy resistance in KRAS-driven NSCLC with diverse mutational profiles (MYCOMBIO).
2021-2024.
PI: Laura Soucek

Proyecto financiado por el Ministerio de Economía y Competitividad

El presente proyecto está cofinanciado por el Fondo Europeo de Desarrollo Regional. Objetivo Temático: Promover el desarrollo tecnológico, la innovación y una investigación de calidad.

Ph.D. Fellowships from FIS– Fondo de Investigación en Salud (Health Research Fund) and Ministerio de Educación y Formación Profesional (Spanish Ministry of Education and Professional Training) University Professorship Training (FPU), awarded to Fabio Giuntini and Íñigo Larreategui, respectively.

Fundación BBVA
Institutional grant, the VHIO-BBVA Foundation’s Immunotherapy & Immunology Program (CAIMI).

Notícies Relacionades